- Home
- MOV vs ALT Comparison
MOV vs ALT Comparison
Compare MOV & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOV
- ALT
- Stock Information
- Founded
- MOV 1961
- ALT 1997
- Country
- MOV United States
- ALT United States
- Employees
- MOV N/A
- ALT N/A
- Industry
- MOV Consumer Specialties
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- MOV Consumer Discretionary
- ALT Health Care
- Exchange
- MOV Nasdaq
- ALT Nasdaq
- Market Cap
- MOV 339.1M
- ALT 292.0M
- IPO Year
- MOV 1993
- ALT N/A
- Fundamental
- Price
- MOV $18.27
- ALT $3.83
- Analyst Decision
- MOV Strong Buy
- ALT Strong Buy
- Analyst Count
- MOV 1
- ALT 6
- Target Price
- MOV $31.50
- ALT $17.40
- AVG Volume (30 Days)
- MOV 145.4K
- ALT 3.0M
- Earning Date
- MOV 08-28-2025
- ALT 08-12-2025
- Dividend Yield
- MOV 7.66%
- ALT N/A
- EPS Growth
- MOV N/A
- ALT N/A
- EPS
- MOV 0.77
- ALT N/A
- Revenue
- MOV $655,597,000.00
- ALT $20,000.00
- Revenue This Year
- MOV $0.71
- ALT N/A
- Revenue Next Year
- MOV N/A
- ALT $761,880.20
- P/E Ratio
- MOV $23.68
- ALT N/A
- Revenue Growth
- MOV 0.79
- ALT N/A
- 52 Week Low
- MOV $12.85
- ALT $2.90
- 52 Week High
- MOV $24.47
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- MOV 70.66
- ALT 51.79
- Support Level
- MOV $16.75
- ALT $3.35
- Resistance Level
- MOV $17.55
- ALT $3.66
- Average True Range (ATR)
- MOV 0.49
- ALT 0.19
- MACD
- MOV 0.20
- ALT 0.07
- Stochastic Oscillator
- MOV 99.42
- ALT 86.18
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.